341 related articles for article (PubMed ID: 33932095)
1. Sputum cell-free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR-TKIs.
Wang Z; Li X; Zhang L; Xu Y; Wang M; Liang L; Jiao P; Li Y; He S; Du J; He L; Tang M; Sun M; Yang L; Di J; Zhu G; Li L; Liu D
Cancer Med; 2021 May; 10(10):3323-3331. PubMed ID: 33932095
[TBL] [Abstract][Full Text] [Related]
2. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
[TBL] [Abstract][Full Text] [Related]
3. Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation.
Lee SH; Kim EY; Kim A; Chang YS
Cancer Biol Ther; 2020 Aug; 21(8):741-748. PubMed ID: 32543264
[TBL] [Abstract][Full Text] [Related]
4. Sputum Cell-Free DNA: Valued Surrogate Sample for Detection of EGFR Mutation in Patients with Advanced Lung Adenocarcinoma.
Wang Z; Zhang L; Li L; Li X; Xu Y; Wang M; Liang L; Jiao P; Li Y; He S; Du J; He L; Tang M; Sun M; Yang L; Di J; Zhu G; Shi H; Liu D
J Mol Diagn; 2020 Jul; 22(7):934-942. PubMed ID: 32407801
[TBL] [Abstract][Full Text] [Related]
5. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
[TBL] [Abstract][Full Text] [Related]
7. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
[TBL] [Abstract][Full Text] [Related]
8. High-throughput sequencing reveals distinct genetic features and clinical implications of NSCLC with de novo and acquired EGFR T790M mutation.
Tian P; Wang Y; Wang W; Li Y; Wang K; Cheng X; Tang Y; Han-Zhang H; Ye J; Chuai S; Li W
Lung Cancer; 2018 Oct; 124():205-210. PubMed ID: 30268462
[TBL] [Abstract][Full Text] [Related]
9. EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.
Buder A; Setinek U; Hochmair MJ; Schwab S; Kirchbacher K; Keck A; Burghuber OC; Pirker R; Filipits M
Target Oncol; 2019 Apr; 14(2):197-203. PubMed ID: 30810887
[TBL] [Abstract][Full Text] [Related]
10. Association between advanced NSCLC T790 M EGFR-TKI secondary resistance and prognosis: A observational study.
Wang Y; Wei Y; Ma X; Ma X; Gong P
Medicine (Baltimore); 2018 Jul; 97(28):e11346. PubMed ID: 29995771
[TBL] [Abstract][Full Text] [Related]
11. Detection of EGFR-Activating and T790M Mutations Using Liquid Biopsy in Patients With EGFR-Mutated Non-Small-Cell Lung Cancer Whose Disease Has Progressed During Treatment With First- and Second-Generation Tyrosine Kinase Inhibitors: A Multicenter Real-Life Retrospective Study.
Minari R; Mazzaschi G; Bordi P; Gnetti L; Alberti G; Altimari A; Gruppioni E; Sperandi F; Parisi C; Guaitoli G; Bettelli S; Longo L; Bertolini F; Pagano M; Bonelli C; Tagliavini E; Nicoli D; Ubiali A; Zangrandi A; Trubini S; Proietto M; Fiorentino M; Tiseo M;
Clin Lung Cancer; 2020 Sep; 21(5):e464-e473. PubMed ID: 32276870
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the Amplification Refractory Mutation System, Super Amplification Refractory Mutation System, and Droplet Digital PCR for T790 M Mutation Detection in Non-small Cell Lung Cancer after Failure of Tyrosine Kinase Inhibitor Treatment.
Zhu L; Zhang S; Xun Y; Jiang Y; Xia B; Chen X; Wang L; Jiang H; Ma S
Pathol Oncol Res; 2018 Oct; 24(4):843-851. PubMed ID: 28868565
[TBL] [Abstract][Full Text] [Related]
13. Plasma epidermal growth factor receptor mutation testing with a chip-based digital PCR system in patients with advanced non-small cell lung cancer.
Kasahara N; Kenmotsu H; Serizawa M; Umehara R; Ono A; Hisamatsu Y; Wakuda K; Omori S; Nakashima K; Taira T; Naito T; Murakami H; Koh Y; Mori K; Endo M; Nakajima T; Yamada M; Kusuhara M; Takahashi T
Lung Cancer; 2017 Apr; 106():138-144. PubMed ID: 28285688
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of PCR-HRM, RFLP, and direct sequencing as simple and cost-effective methods to detect common EGFR mutations in plasma cell-free DNA of non-small cell lung cancer patients.
Zaini J; Syahruddin E; Yunus M; Andarini SL; Hudoyo A; Masykura N; Yasril R; Ridwanuloh A; Hidajat H; Nurwidya F; Suharsono S; Utomo ARH
Cancer Rep (Hoboken); 2019 Aug; 2(4):e1159. PubMed ID: 32721094
[TBL] [Abstract][Full Text] [Related]
15. Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma.
Wang Z; Li L; Wang Y; Li X; Xu Y; Wang M; Liang L; Wu X; Tang M; Li Y; He S; Du J; He L; Sun M; Yang L; Di J; Gai F; Liu D
Cancer Cytopathol; 2023 Feb; 131(2):110-116. PubMed ID: 36103360
[TBL] [Abstract][Full Text] [Related]
16. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
[TBL] [Abstract][Full Text] [Related]
17. Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
Wang ZF; Ren SX; Li W; Gao GH
BMC Cancer; 2018 Feb; 18(1):148. PubMed ID: 29409466
[TBL] [Abstract][Full Text] [Related]
18. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
[TBL] [Abstract][Full Text] [Related]
19. The T790M resistance mutation in EGFR is only found in cfDNA from erlotinib-treated NSCLC patients that harbored an activating EGFR mutation before treatment.
Demuth C; Madsen AT; Weber B; Wu L; Meldgaard P; Sorensen BS
BMC Cancer; 2018 Feb; 18(1):191. PubMed ID: 29448920
[TBL] [Abstract][Full Text] [Related]
20. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Gelatti ACZ; Drilon A; Santini FC
Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
